This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the eighth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the seventh installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Hepatitis B is a life-threatening liver infection that is caused by the hepatitis B virus, whereas, hepatitis D infection only occurs in people who are infected with the hepatitis B virus. It ...

Bulevirtide (Hepcludex) monotherapy significantly reduces the load of hepatitis delta virus (HDV) and is safe in difficult-to-treat patients with compensated cirrhosis and clinically significant ...

You’re probably aware that there is more than one form of hepatitis, but it’s understandable if you can’t keep them all straight. After all, there are five main forms of the disease. But while they ...

WASHINGTON -- Hepatitis D may be the loneliest hepatitis virus around, but it's still here and needs attention, several speakers said here at the Digestive Disease Week meeting. "Even though it's been ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Up to 57% of patients with chronic hepatitis D virus ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Meg Doherty, MD, MPH, PhD, Director Global HIV, Hepatitis and STI Programmes at WHO, about ...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...